MX2020012980A - Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. - Google Patents

Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.

Info

Publication number
MX2020012980A
MX2020012980A MX2020012980A MX2020012980A MX2020012980A MX 2020012980 A MX2020012980 A MX 2020012980A MX 2020012980 A MX2020012980 A MX 2020012980A MX 2020012980 A MX2020012980 A MX 2020012980A MX 2020012980 A MX2020012980 A MX 2020012980A
Authority
MX
Mexico
Prior art keywords
methods
compositions
plasma exposure
tetrahydrobiopterin
increasing
Prior art date
Application number
MX2020012980A
Other languages
English (en)
Inventor
Neil Smith
Jonathan Reis
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of MX2020012980A publication Critical patent/MX2020012980A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención presenta composiciones farmacéuticas que incluyen sepiapterina, o una sal farmacéuticamente aceptable de la misma, y métodos para el tratamiento de trastornos relacionados con el BH4. En algunas modalidades, estas composiciones y métodos dan por resultado un incremento en la exposición plasmática de BH4.
MX2020012980A 2018-05-30 2019-05-30 Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. MX2020012980A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677926P 2018-05-30 2018-05-30
US201862771397P 2018-11-26 2018-11-26
US201962822365P 2019-03-22 2019-03-22
GC201937662 2019-05-28
PCT/US2019/034515 WO2019232126A1 (en) 2018-05-30 2019-05-30 Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Publications (1)

Publication Number Publication Date
MX2020012980A true MX2020012980A (es) 2021-04-29

Family

ID=68699016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012980A MX2020012980A (es) 2018-05-30 2019-05-30 Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.

Country Status (8)

Country Link
US (1) US20210161901A1 (es)
EP (1) EP3801534A4 (es)
JP (1) JP2021525746A (es)
CN (1) CN112654356A (es)
BR (1) BR112020024329A2 (es)
CA (1) CA3102105A1 (es)
MX (1) MX2020012980A (es)
WO (1) WO2019232126A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277382A1 (en) * 2018-05-30 2021-01-21 Ptc Therapeutics Mp, Inc. Methods for increasing sepiapterin plasma exposure
CA3165636A1 (en) * 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4029519A1 (en) * 2007-04-11 2022-07-20 BioMarin Pharmaceutical Inc. Tetrahydrobiopterin for treating conditions associated with elevated phenylalanine levels
US20130197000A1 (en) * 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US11072614B2 (en) * 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP2020532535A (ja) * 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
CN112543758A (zh) * 2018-05-30 2021-03-23 Ptc医疗Mp公司 墨蝶呤的药学上可接受的盐
CA3150003A1 (en) * 2019-09-25 2021-04-01 Niel SMITH METHODS OF TREATING HYPERPHENYLALANINEMIA

Also Published As

Publication number Publication date
BR112020024329A2 (pt) 2021-02-23
CA3102105A1 (en) 2019-12-05
EP3801534A1 (en) 2021-04-14
US20210161901A1 (en) 2021-06-03
CN112654356A (zh) 2021-04-13
WO2019232126A1 (en) 2019-12-05
EP3801534A4 (en) 2022-03-16
JP2021525746A (ja) 2021-09-27

Similar Documents

Publication Publication Date Title
MX2020012980A (es) Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina.
MX2020002271A (es) Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2023014145A (es) Oligonucleotidos modificados y metodos de uso.
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
JOP20210305A1 (ar) صيغ إيماتينيب وتصنيعها واستخداماتها
GEP20247585B (en) Furoindazole derivatives
MX2023013844A (es) Metodos para tratar trastornos mieloproliferativos.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2022001535A (es) Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion.
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using